{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T10:36:16Z","timestamp":1771583776617,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Science and Technology Research Project of Education Department of Jiangxi Province","award":["No. GJJ2200121"],"award-info":[{"award-number":["No. GJJ2200121"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10067-026-07933-2","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T07:44:09Z","timestamp":1768981449000},"page":"1625-1636","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Global research status and trends in the treatment of ankylosing spondylitis from 2005 to 2024: a bibliometric analysis"],"prefix":"10.1007","volume":"45","author":[{"given":"Zhaoxia","family":"Zeng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayi","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiawang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0726-019X","authenticated-orcid":false,"given":"Wugen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"7933_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41413-019-0057-8","volume":"7","author":"W Zhu","year":"2019","unstructured":"Zhu W, He X, Cheng K, Zhang L, Chen D, Wang X, Qiu G, Cao X, Weng X (2019) Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Res 7:22. https:\/\/doi.org\/10.1038\/s41413-019-0057-8","journal-title":"Bone Res"},{"issue":"3","key":"7933_CR2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1136\/ard.2005.040758","volume":"65","author":"J Braun","year":"2006","unstructured":"Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D (2006) First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65(3):316\u2013320. https:\/\/doi.org\/10.1136\/ard.2005.040758","journal-title":"Ann Rheum Dis"},{"key":"7933_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.637829","volume":"12","author":"C Schinocca","year":"2021","unstructured":"Schinocca C, Rizzo C, Fasano S, Grasso G, La Barbera L, Ciccia F, Guggino G (2021) Role of the IL-23\/IL-17 pathway in rheumatic diseases: an overview. Front Immunol 12:637829. https:\/\/doi.org\/10.3389\/fimmu.2021.637829","journal-title":"Front Immunol"},{"issue":"3","key":"7933_CR4","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.38967","volume":"67","author":"ME Costello","year":"2015","unstructured":"Costello ME, Ciccia F, Willner D, Warrington N, Robinson PC, Gardiner B, Marshall M, Kenna TJ, Triolo G, Brown MA (2015) Brief report: intestinal dysbiosis in ankylosing spondylitis. Arthritis Rheumatol 67(3):686\u2013691. https:\/\/doi.org\/10.1002\/art.38967","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"7933_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/14712598.2019.1554053","volume":"19","author":"D Wendling","year":"2019","unstructured":"Wendling D, Verhoeven F, Prati C (2019) Anti-IL-17 monoclonal antibodies for the treatment of ankylosing spondylitis. Expert Opin Biol Ther 19(1):55\u201364. https:\/\/doi.org\/10.1080\/14712598.2019.1554053","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"7933_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","volume":"33","author":"A Tv","year":"2019","unstructured":"Tv A, Haikarainen T, Raivola J, Silvennoinen O (2019) Selective JAKinibs: prospects in inflammatory and autoimmune diseases. BioDrugs 33(1):15\u201332. https:\/\/doi.org\/10.1007\/s40259-019-00333-w","journal-title":"BioDrugs"},{"issue":"10162","key":"7933_CR7","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1016\/s0140-6736(18)32463-2","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Baraliakos X, Gensler LS, Maksymowych WP, Tseluyko V, Nadashkevich O, Abi-Saab W, Tasset C, Meuleners L, Besuyen R, Hendrikx T, Mozaffarian N, Liu K, Greer JM, Deodhar A, Landew\u00e9 R (2018) Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet 392(10162):2378\u20132387. https:\/\/doi.org\/10.1016\/s0140-6736(18)32463-2","journal-title":"Lancet"},{"key":"7933_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01520","volume":"11","author":"H Shi","year":"2020","unstructured":"Shi H, Chen L, Ridley A, Zaarour N, Brough I, Caucci C, Smith JE, Bowness P (2020) GM-CSF primes proinflammatory monocyte responses in ankylosing spondylitis. Front Immunol 11:1520. https:\/\/doi.org\/10.3389\/fimmu.2020.01520","journal-title":"Front Immunol"},{"issue":"2","key":"7933_CR9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.apmr.2017.07.015","volume":"99","author":"V P\u00e9courneau","year":"2018","unstructured":"P\u00e9courneau V, Degbo\u00e9 Y, Barnetche T, Cantagrel A, Constantin A, Ruyssen-Witrand A (2018) Effectiveness of exercise programs in ankylosing spondylitis: a meta-analysis of randomized controlled trials. Arch Phys Med Rehabil 99(2):383-389.e381. https:\/\/doi.org\/10.1016\/j.apmr.2017.07.015","journal-title":"Arch Phys Med Rehabil"},{"issue":"12","key":"7933_CR10","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1517\/17425255.2012.741120","volume":"8","author":"RJ Lories","year":"2012","unstructured":"Lories RJ (2012) Etoricoxib and the treatment of ankylosing spondylitis. Expert Opin Drug Metab Toxicol 8(12):1599\u20131608. https:\/\/doi.org\/10.1517\/17425255.2012.741120","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"7933_CR11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.berh.2006.03.003","volume":"20","author":"N Akkoc","year":"2006","unstructured":"Akkoc N, van der Linden S, Khan MA (2006) Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy. Best Pract Res Clin Rheumatol 20(3):539\u2013557. https:\/\/doi.org\/10.1016\/j.berh.2006.03.003","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"7933_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041630","author":"GM Leone","year":"2023","unstructured":"Leone GM, Mangano K, Petralia MC, Nicoletti F, Fagone P (2023) Past, present and (foreseeable) future of biological anti-TNF alpha therapy. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12041630","journal-title":"J Clin Med"},{"issue":"1","key":"7933_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/cei.12670","volume":"183","author":"H Jethwa","year":"2016","unstructured":"Jethwa H, Bowness P (2016) The interleukin (IL)-23\/IL-17 axis in ankylosing spondylitis: new advances and potentials for treatment. Clin Exp Immunol 183(1):30\u201336. https:\/\/doi.org\/10.1111\/cei.12670","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"7933_CR14","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1535-7163.Mct-22-0323","volume":"21","author":"RP Agashe","year":"2022","unstructured":"Agashe RP, Lippman SM, Kurzrock R (2022) JAK: not just another kinase. Mol Cancer Ther 21(12):1757\u20131764. https:\/\/doi.org\/10.1158\/1535-7163.Mct-22-0323","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"7933_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102640","volume":"49","author":"W Hassan","year":"2024","unstructured":"Hassan W, Duarte AE (2024) Bibliometric analysis: a few suggestions. Curr Probl Cardiol 49(8):102640. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102640","journal-title":"Curr Probl Cardiol"},{"issue":"7","key":"7933_CR16","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1007\/s10238-023-01102-4","volume":"23","author":"X Li","year":"2023","unstructured":"Li X, Yu W, Jia Z, Li J, Liu Y, Yang J (2023) Frontiers of ankylosing spondylitis research: an analysis from the top 100 most influential articles in the field. Clin Exp Med 23(7):3019\u20133040. https:\/\/doi.org\/10.1007\/s10238-023-01102-4","journal-title":"Clin Exp Med"},{"key":"7933_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1328439","volume":"14","author":"W Zhang","year":"2023","unstructured":"Zhang W, Li M, Li X, Wang X, Liu Y, Yang J (2023) Global trends and research status in ankylosing spondylitis clinical trials: a bibliometric analysis of the last 20 years. Front Immunol 14:1328439. https:\/\/doi.org\/10.3389\/fimmu.2023.1328439","journal-title":"Front Immunol"},{"issue":"5","key":"7933_CR18","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/jrsm.1729","volume":"15","author":"M Gusenbauer","year":"2024","unstructured":"Gusenbauer M (2024) Beyond Google scholar, Scopus, and Web of Science: an evaluation of the backward and forward citation coverage of 59 databases\u2019 citation indices. Res Synth Methods 15(5):802\u2013817. https:\/\/doi.org\/10.1002\/jrsm.1729","journal-title":"Res Synth Methods"},{"issue":"4","key":"7933_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41584-022-00761-z","volume":"18","author":"A Danve","year":"2022","unstructured":"Danve A, Deodhar A (2022) Treatment of axial spondyloarthritis: an update. Nat Rev Rheumatol 18(4):205\u2013216. https:\/\/doi.org\/10.1038\/s41584-022-00761-z","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"7933_CR20","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/ard-2022-222608","volume":"81","author":"D van der Heijde","year":"2022","unstructured":"van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman RD, Kameda H, Zeng X, Sui Y, Bu X, Pangan AL, Wung P, Song IH (2022) Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis 81(11):1515\u20131523. https:\/\/doi.org\/10.1136\/ard-2022-222608","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"7933_CR21","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","volume":"80","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, Wang L, Wu J, Menon S, Wang C, Dina O, Fallon L, Kanik KS, van der Heijde D (2021) Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 80(8):1004\u20131013. https:\/\/doi.org\/10.1136\/annrheumdis-2020-219601","journal-title":"Ann Rheum Dis"},{"issue":"26","key":"7933_CR22","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB (2015) Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med 373(26):2534\u20132548. https:\/\/doi.org\/10.1056\/NEJMoa1505066","journal-title":"N Engl J Med"},{"issue":"10","key":"7933_CR23","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1517\/14656566.2015.1052744","volume":"16","author":"C Palazzi","year":"2015","unstructured":"Palazzi C, D\u2019Angelo S, Gilio M, Leccese P, Padula A, Olivieri I (2015) Pharmacological therapy of spondyloarthritis. Expert Opin Pharmacother 16(10):1495\u20131504. https:\/\/doi.org\/10.1517\/14656566.2015.1052744","journal-title":"Expert Opin Pharmacother"},{"issue":"9","key":"7933_CR24","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.2165\/00003495-200565090-00006","volume":"65","author":"DM Robinson","year":"2005","unstructured":"Robinson DM, Keating GM (2005) Infliximab: in ankylosing spondylitis. Drugs 65(9):1283\u20131291. https:\/\/doi.org\/10.2165\/00003495-200565090-00006","journal-title":"Drugs"},{"issue":"1","key":"7933_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1517\/14740338.2012.633509","volume":"11","author":"TA Kerensky","year":"2012","unstructured":"Kerensky TA, Gottlieb AB, Yaniv S, Au SC (2012) Etanercept: efficacy and safety for approved indications. Expert Opin Drug Saf 11(1):121\u2013139. https:\/\/doi.org\/10.1517\/14740338.2012.633509","journal-title":"Expert Opin Drug Saf"},{"key":"7933_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.700570","volume":"12","author":"Z Chen","year":"2021","unstructured":"Chen Z, Zheng X, Wu X, Wu J, Li X, Wei Q, Zhang X, Fang L, Jin O, Gu J (2021) Adalimumab therapy restores the gut microbiota in patients with ankylosing spondylitis. Front Immunol 12:700570. https:\/\/doi.org\/10.3389\/fimmu.2021.700570","journal-title":"Front Immunol"},{"issue":"10","key":"7933_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-021-01043-5","volume":"23","author":"M Bittar","year":"2021","unstructured":"Bittar M, Yong WC, Magrey M, Khan MA (2021) Worldwide differences in clinical phenotype of axial spondyloarthritis. Curr Rheumatol Rep 23(10):76. https:\/\/doi.org\/10.1007\/s11926-021-01043-5","journal-title":"Curr Rheumatol Rep"},{"issue":"9","key":"7933_CR28","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","volume":"78","author":"DG McGonagle","year":"2019","unstructured":"McGonagle DG, McInnes IB, Kirkham BW, Sherlock J, Moots R (2019) The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum Dis 78(9):1167\u20131178. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215356","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"7933_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2023.101897","volume":"37","author":"MGH van de Sande","year":"2023","unstructured":"van de Sande MGH, Elewaut D (2023) Pathophysiology and immunolgical basis of axial spondyloarthritis. Best Pract Res Clin Rheumatol 37(3):101897. https:\/\/doi.org\/10.1016\/j.berh.2023.101897","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"Suppl 11","key":"7933_CR30","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1002\/acr.20575","volume":"63","author":"J Zochling","year":"2011","unstructured":"Zochling J (2011) Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res (Hoboken) 63(Suppl 11):S47-58. https:\/\/doi.org\/10.1002\/acr.20575","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"7933_CR31","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s11926-022-01091-5","volume":"24","author":"AS De Craemer","year":"2022","unstructured":"De Craemer AS, \u0141ukasik Z, Carron P (2022) Use of imaging in axial spondyloarthritis for diagnosis and assessment of disease remission in the year 2022. Curr Rheumatol Rep 24(12):383\u2013397. https:\/\/doi.org\/10.1007\/s11926-022-01091-5","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"7933_CR32","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/BOR.0b013e3283620777","volume":"25","author":"N Davey-Ranasinghe","year":"2013","unstructured":"Davey-Ranasinghe N, Deodhar A (2013) Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol 25(4):509\u2013516. https:\/\/doi.org\/10.1097\/BOR.0b013e3283620777","journal-title":"Curr Opin Rheumatol"},{"issue":"Suppl4","key":"7933_CR33","doi-asserted-by":"publisher","first-page":"iv6","DOI":"10.1093\/rheumatology\/keaa250","volume":"59","author":"D Poddubnyy","year":"2020","unstructured":"Poddubnyy D (2020) Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritis. Rheumatology (Oxford) 59(Suppl4):iv6\u2013iv17. https:\/\/doi.org\/10.1093\/rheumatology\/keaa250","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"7933_CR34","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"M Rudwaleit","year":"2009","unstructured":"Rudwaleit M, van der Heijde D, Landew\u00e9 R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowych WP, Mielants H, S\u00f8rensen IJ, Ozgocmen S, Roussou E, Sieper J (2009) The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 68(6):777\u2013783. https:\/\/doi.org\/10.1136\/ard.2009.108233","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 4","key":"7933_CR35","doi-asserted-by":"publisher","first-page":"iv61","DOI":"10.1136\/ard.2005.042432","volume":"64","author":"J Sieper","year":"2005","unstructured":"Sieper J, Rudwaleit M (2005) How early should ankylosing spondylitis be treated with tumour necrosis factor blockers? Ann Rheum Dis 64(Suppl 4):iv61-64. https:\/\/doi.org\/10.1136\/ard.2005.042432","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"7933_CR36","doi-asserted-by":"publisher","first-page":"iii25","DOI":"10.1136\/ard.2006.058461","volume":"65","author":"MM Ward","year":"2006","unstructured":"Ward MM (2006) Outcomes in ankylosing spondylitis: what makes the assessment of treatment effects in ankylosing spondylitis different? Ann Rheum Dis 65(Suppl 3):iii25-28. https:\/\/doi.org\/10.1136\/ard.2006.058461","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"7933_CR37","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1007\/s12035-021-02293-1","volume":"58","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Fan R, Botchway BOA, Zhang Y, Liu X (2021) Infliximab can improve traumatic brain injury by suppressing the tumor necrosis factor alpha pathway. Mol Neurobiol 58(6):2803\u20132811. https:\/\/doi.org\/10.1007\/s12035-021-02293-1","journal-title":"Mol Neurobiol"},{"issue":"6","key":"7933_CR38","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2004.029900","volume":"64","author":"SN Nikas","year":"2005","unstructured":"Nikas SN, Alamanos Y, Voulgari PV, Pliakou XI, Papadopoulos CG, Drosos AA (2005) Infliximab treatment in ankylosing spondylitis: an observational study. Ann Rheum Dis 64(6):940\u2013942. https:\/\/doi.org\/10.1136\/ard.2004.029900","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"7933_CR39","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3899\/jrheum.081033","volume":"36","author":"B Dijkmans","year":"2009","unstructured":"Dijkmans B, Emery P, Hakala M, Leirisalo-Repo M, Mola EM, Paolozzi L, Salvarani C, Sanmarti R, Sibilia J, Sieper J, Van Den Bosch F, van der Heijde D, van der Linden S, Wajdula J (2009) Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 36(6):1256\u20131264. https:\/\/doi.org\/10.3899\/jrheum.081033","journal-title":"J Rheumatol"},{"issue":"9","key":"7933_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-013-0356-9","volume":"15","author":"J Sieper","year":"2013","unstructured":"Sieper J (2013) Treatment challenges in axial spondylarthritis and future directions. Curr Rheumatol Rep 15(9):356. https:\/\/doi.org\/10.1007\/s11926-013-0356-9","journal-title":"Curr Rheumatol Rep"},{"issue":"12","key":"7933_CR41","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1002\/art.39805","volume":"68","author":"AA Deodhar","year":"2016","unstructured":"Deodhar AA, Dougados M, Baeten DL, Cheng-Chung Wei J, Geusens P, Readie A, Richards HB, Martin R, Porter B (2016) Effect of secukinumab on patient-reported outcomes in patients with active ankylosing spondylitis: a phase III randomized trial (MEASURE 1). Arthritis Rheumatol 68(12):2901\u20132910. https:\/\/doi.org\/10.1002\/art.39805","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"7933_CR42","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40259-016-0193-2","volume":"30","author":"HA Blair","year":"2016","unstructured":"Blair HA, Deeks ED (2016) Infliximab biosimilar (CT-P13; Infliximab-dyyb): a review in autoimmune inflammatory diseases. Biodrugs 30(5):469\u2013480. https:\/\/doi.org\/10.1007\/s40259-016-0193-2","journal-title":"Biodrugs"},{"issue":"6","key":"7933_CR43","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrrheum.2017.56","volume":"13","author":"V Ranganathan","year":"2017","unstructured":"Ranganathan V, Gracey E, Brown MA, Inman RD, Haroon N (2017) Pathogenesis of ankylosing spondylitis - recent advances and future directions. Nat Rev Rheumatol 13(6):359\u2013367. https:\/\/doi.org\/10.1038\/nrrheum.2017.56","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"7933_CR44","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1016\/s2665-9913(20)30066-7","volume":"2","author":"H Marzo-Ortega","year":"2020","unstructured":"Marzo-Ortega H, Sieper J, Kivitz AJ, Blanco R, Cohen M, Pavelka K, Delicha EM, Stefanska A, Richards HB, Rohrer S (2020) 5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial. Lancet Rheumatol 2(6):e339\u2013e346. https:\/\/doi.org\/10.1016\/s2665-9913(20)30066-7","journal-title":"Lancet Rheumatol"},{"key":"7933_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/biom10101461","author":"A Sharip","year":"2020","unstructured":"Sharip A, Kunz J (2020) Understanding the pathogenesis of spondyloarthritis. Biomolecules. https:\/\/doi.org\/10.3390\/biom10101461","journal-title":"Biomolecules"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-07933-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-07933-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-07933-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T09:53:27Z","timestamp":1771581207000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-07933-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7933"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-07933-2","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"assertion":[{"value":"11 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.\u00a0","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Clinical trial is not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Clinical trial number"}},{"value":"None.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}